View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
July 26, 2012

Merck study shows potential for eradicating hidden HIV pools

Merck has provided early evidence of the use of drugs to eradicate hidden reservoirs of the HIV virus in the body.

By Nikitha Ladda

Merck has provided early evidence of the use of drugs to eradicate hidden reservoirs of the HIV virus in the body.

Writing in the scientific journal Nature, Merck Research Laboratories said there is potential for histone deacetylase inhibitors, a group of compounds used to treat epilepsy, to attack "dormant virus pools".

The firm collaborated with researchers from the University of North Carolina (UNC), the Harvard School of Public Health, the National Cancer Institute, and the University of California to conduct the study.

Merck Research Laboratories vice president Daria Hazuda said, "We believe that the disruption and clearance of these virus reservoirs is a critical first step to the daunting challenge of finding a cure for HIV/AIDS."

"We are excited about this pioneering research and remain hopeful for its potential."

This research was first presented in March at the Conference on Retroviruses and Opportunistic Infections in Seattle, and more recently at the International AIDS Conference in Washington DC.

UNC professor of medicine, microbiology and immunology David Margolis, who led the study, said, "This work provides compelling evidence to support a strategy to directly attack and eradicate latent HIV infection."

 

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU